FOLLICULAR HELPER T-CELL LYMPHOMA
Clinical trials for FOLLICULAR HELPER T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new FOLLICULAR HELPER T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for FOLLICULAR HELPER T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a stem cell boost keep T-Cell lymphoma away longer?
Disease control Recruiting nowThis study looks at whether giving high-dose chemotherapy followed by a transplant of the patient's own stem cells can help people with peripheral T-cell lymphoma stay in remission longer than just watching and waiting. About 294 adults aged 18 to 75 who are in their first comple…
Matched conditions: FOLLICULAR HELPER T-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Eastern Cooperative Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental combo targets rare lymphoma in early trial
Disease control Recruiting nowThis phase 1 trial is testing whether adding the drug ruxolitinib to standard CHOP chemotherapy is safe and effective for people with untreated nodal T-follicular helper (TFH) cell lymphoma, a rare type of non-Hodgkin lymphoma. About 20 adults will receive the combination to find…
Matched conditions: FOLLICULAR HELPER T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug may keep rare lymphoma at bay after first treatment
Disease control Recruiting nowThis phase II trial is testing whether the drug duvelisib can help prevent peripheral T-cell lymphoma from coming back after initial therapy. About 25 adults with certain types of T-cell lymphoma will take duvelisib as maintenance treatment. The study will track how long patients…
Matched conditions: FOLLICULAR HELPER T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for tough lymphoma: stem cell transplant trial for Non-Responders
Disease control Recruiting nowThis study is for people with peripheral T-cell lymphoma whose cancer did not shrink or got worse after standard first treatment. It compares a stem cell transplant from a donor to other rescue treatments. The goal is to see which approach helps people live longer and control the…
Matched conditions: FOLLICULAR HELPER T-CELL LYMPHOMA
Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New hope for rare blood cancer: platform trial tests multiple drugs at once
Disease control Recruiting nowThis study is testing three oral drugs—roginolisib, golcadomide, and azacitidine—alone or in combination for people with peripheral T-cell lymphoma that has come back or not responded to treatment. The trial has two phases: Phase 1 finds safe doses, and Phase 2 checks if the drug…
Matched conditions: FOLLICULAR HELPER T-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New hope for Tough-to-Treat T-Cell lymphoma? pacritinib trial opens
Disease control Recruiting nowThis study tests a drug called pacritinib in 100 people with T-cell lymphoma that has returned or not responded to prior therapy. The main goal is to see how many patients have their tumors shrink or disappear. Participants take the drug and are monitored with scans and skin asse…
Matched conditions: FOLLICULAR HELPER T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Can a stem cell transplant stop T-Cell lymphoma from returning?
Disease control Recruiting nowThis study looks at whether a stem cell transplant (using a patient's own cells) after successful first treatment can help control peripheral T-cell lymphoma. About 160 people will either get the transplant or just be monitored. The goal is to see if the transplant delays the can…
Matched conditions: FOLLICULAR HELPER T-CELL LYMPHOMA
Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Stem cell showdown: donor or self? new trial aims to improve lymphoma outcomes
Disease control Recruiting nowThis study compares two types of stem cell transplants for people with peripheral T-cell lymphoma whose cancer only partially responded to first treatment. One group receives their own stem cells, the other receives cells from a matched donor. The goal is to see which approach le…
Matched conditions: FOLLICULAR HELPER T-CELL LYMPHOMA
Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC